ArticleCureus2024
Anti-N-Methyl-D-Aspartate Receptor (Anti-NMDAR) Encephalitis in Small Cell Lung Cancer: A Case Report.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Successful Early Treatment of Anti-N-Methyl-d-Aspartate Receptor Encephalitis Associated With Small Cell Lung Cancer in an Elderly Male Patient: A Case Report.Neuropsychopharmacology reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is an autoimmune encephalitis characterized by psychiatric and neurological symptoms. It often presents as a paraneoplastic manifestation and is rarely associated with small cell lung cancer. While treatment usually involves immunotherapy and treatment of underlying malignancy, the patient's condition can complicate treatment decisions. A 66-year-old man presented to the emergency department with a chief complaint of fever and impaired consciousness. Tests revealed anti-NMDAR encephalitis and small cell lung cancer. Despite immunotherapy, including steroids, intravenous immunoglobulin, and rituximab, chemotherapy was not possible due to the patient's poor condition. Immunotherapy treatment was continued, but there was no improvement in his state of consciousness, and death was confirmed on the 101st day of hospitalization. Anti-NMDAR encephalitis caused by small cell carcinoma is treated with immunotherapy and cancer therapy; only immunotherapy is not enough.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.